Bert Jan Haijema
Overview
Explore the profile of Bert Jan Haijema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Widjaja I, Wicht O, Luytjes W, Leenhouts K, Rottier P, van Kuppeveld F, et al.
J Virol
. 2016 Apr;
90(13):5965-5977.
PMID: 27099320
Unlabelled: Antibodies against the fusion (F) protein of respiratory syncytial virus (RSV) play an important role in the protective immune response to this important respiratory virus. Little is known, however,...
2.
Widjaja I, Rigter A, Jacobino S, van Kuppeveld F, Leenhouts K, Palomo C, et al.
PLoS One
. 2015 Jun;
10(6):e0130829.
PMID: 26107504
The respiratory syncytial virus (RSV) fusion protein F is considered an attractive vaccine candidate especially in its prefusion conformation. We studied whether recombinant soluble RSV F proteins could be stabilized...
3.
Van Braeckel-Budimir N, Haijema B, Leenhouts K
Front Immunol
. 2013 Sep;
4:282.
PMID: 24062748
The successful development of a mucosal vaccine depends critically on the use of a safe and effective immunostimulant and/or carrier system. This review describes the effectiveness and mode of action...
4.
Rigter A, Widjaja I, Versantvoort H, Coenjaerts F, van Roosmalen M, Leenhouts K, et al.
PLoS One
. 2013 Aug;
8(8):e71072.
PMID: 23951084
Respiratory syncytial virus (RSV) is an important cause of respiratory tract disease in infants and the elderly. Currently, no licensed vaccine against RSV is available. Here we describe the development...
5.
de Haan A, Haijema B, Voorn P, Meijerhof T, van Roosmalen M, Leenhouts K
Vaccine
. 2012 Apr;
30(32):4884-91.
PMID: 22537989
Administration of influenza vaccines through the intranasal (IN) route forms an attractive alternative to conventional intramuscular (IM) injection. It is not only a better accepted form of vaccine administration but...
6.
de Haan C, Haijema B, Masters P, Rottier P
Methods Mol Biol
. 2008 Dec;
454:229-36.
PMID: 19057874
Targeted RNA recombination has proven to be a powerful tool for the genetic engineering of the coronavirus genome, particularly in its 3' part. Here we describe procedures for the generation...
7.
de Souza Luna L, Heiser V, Regamey N, Panning M, Drexler J, Mulangu S, et al.
J Clin Microbiol
. 2007 Jan;
45(3):1049-52.
PMID: 17229859
A nonfluorescent low-cost, low-density oligonucleotide array was designed for detecting the whole coronavirus genus after reverse transcription (RT)-PCR. The limit of detection was 15.7 copies/reaction. The clinical detection limit in...
8.
de Haan C, Li Z, Te Lintelo E, Bosch B, Haijema B, Rottier P
J Virol
. 2005 Oct;
79(22):14451-6.
PMID: 16254381
Only a relatively few mutations in its spike protein allow the murine coronavirus to switch from a murine-restricted tropism to an extended host range by being passaged in vitro. One...
9.
Rottier P, Nakamura K, Schellen P, Volders H, Haijema B
J Virol
. 2005 Oct;
79(22):14122-30.
PMID: 16254347
In feline coronavirus (FCoV) pathogenesis, the ability to infect macrophages is an essential virulence factor. Whereas the low-virulence feline enteric coronavirus (FECV) isolates primarily replicate in the epithelial cells of...
10.
de Haan C, Haijema B, Boss D, Heuts F, Rottier P
J Virol
. 2005 Sep;
79(20):12742-51.
PMID: 16188977
Coronaviruses are enveloped, positive-stranded RNA viruses considered to be promising vectors for vaccine development, as (i) genes can be deleted, resulting in attenuated viruses; (ii) their tropism can be modified...